MedPath

Treatment of thromBocytopenia with EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients with Immune ThrombocytoPenia.

Phase 3
Withdrawn
Conditions
10035534
10003816
ITP
Immune trombocytopenia
Registration Number
NL-OMON46896
Lead Sponsor
HagaZiekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
15
Inclusion Criteria

1. Primary or secondary ITP (according to the ASH 2011 guidelines);
2. Platelet count below the surgical platelet count threshold (50 x109/L for minor surgery; 100
x 109/L for major surgery);
3. 18 years of age or older;
4. On stable doses of concomitant ITP medications (or no medication) for at least 2 weeks
(i.e. the dose administered has not changed);
5. At least 3-weeks lead time available between randomization and scheduled surgery;
6. IVIG and Eltrombopag are acceptable ITP treatment options for this patient;
7. Able to provide informed consent.

Exclusion Criteria

1. Pregnancy or breastfeeding;
2. Treatment with IVIG within the last 2 weeks;
3. Treatment with a thrombopoietin receptor agonist (eltrombopag or romiplostim) within the
last 4 weeks;
4. AST, ALT above 2X upper limit of normal;
5. Bilirubin above 1.5X upper limit of normal in the absence of clinically benign liver disorder
(e.g. Gilberts syndrome);
6. Deep vein thrombosis, myocardial infarction, thrombotic stroke or arterial thrombosis in the
last 12 months;
7. History of bone marrow reticulin or fibrosis;
8. Known liver cirrhosis;
9. Active malignancy (defined as requiring treatment or palliation within the last 6 months).
10. Any additional laboratory test result, health related illness or other diagnosis which, in the
opinion of the treating physician, may put the subject's health or safety at risk.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Proportion of patients achieving the platelet count threshold before surgery<br /><br>and maintaining platelet counts within the<br /><br>target range until 7 days after surgical hemostasis is achieved without the use<br /><br>of ITP rescue treatment.</p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath